{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-002417","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.359992+00:00","generated_at":"2026-06-20T00:40:34.564556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arrowhead Pharma Q1 revenue $62.5M, net loss narrows to $0.39; sells olpasiran royalty for $250M","bullets":["Revenue $62.5M vs $27.4M; net loss $41.3M ($0.39/share) improved from $62.9M ($0.60).","Total cash and investments $617.6M at Dec 31, up from $482.3M at Sep 30.","Earned $25M milestone from Amgen for olpasiran Phase 3 start, $15M from Horizon for HZN-457 Phase 1 start.","Sold olpasiran royalty interest to Royalty Pharma for $250M upfront plus up to $160M contingent payments.","Topline SEQUOIA study: fibrosis regression in 50% of fazirsiran-treated AATD patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-002417","json":"https://secwatch.observer/filing/0001628280-23-002417.json","markdown":"https://secwatch.observer/filing/0001628280-23-002417.md","text":"https://secwatch.observer/filing/0001628280-23-002417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828023002417/0001628280-23-002417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828023002417/arwr-20230206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:40:34.564556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"311da3cc6d7051abc26113ac5b7e0ddac84370b6","claim":"ARROWHEAD PHARMACEUTICALS, INC. reported first quarter ended December 31, 2022 results: revenue $62,546, net income ($41,325), EPS $(0.39).","evidence_excerpt":"INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended December 31, OPERATING SUMMARY 2022 2021 (unaudited) Revenue $ 62,546 $ 27,439 Operating Expenses: Research and development 83,695 65,765 General and administrative expenses 20,985 24,995 Total Operating Expenses 104,680 90,760 Operating loss","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023002417/0001628280-23-002417-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended December 31, 2022"},{"label":"Revenue","value":"$62,546"},{"label":"Net income","value":"($41,325)"},{"label":"EPS","value":"$(0.39)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}